Medication Use in Multiple Sclerosis: A Population-Based Comparison With the General Danish Population.

IF 3.9 2区医学 Q1 CLINICAL NEUROLOGY

Annals of Clinical and Translational Neurology Pub Date : 2025-07-31 DOI:10.1002/acn3.70155

Josefine Windfeld-Mathiasen, Henrik Horwitz, Ida M Heerfordt, Elisabeth Framke, Melinda Magyari

{"title":"Medication Use in Multiple Sclerosis: A Population-Based Comparison With the General Danish Population.","authors":"Josefine Windfeld-Mathiasen, Henrik Horwitz, Ida M Heerfordt, Elisabeth Framke, Melinda Magyari","doi":"10.1002/acn3.70155","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease-modifying therapies.Methods: We conducted a nationwide, registry-based study in Denmark. All residents with a diagnosis of multiple sclerosis aged 20-80 years and alive on January 1, 2023, were included and followed for 1 year. Each patient was matched with 10 individuals from the general population based on age, sex, and residence. Prescription data were obtained from the Danish National Prescription Registry and categorized using the Anatomical Therapeutic Chemical classification. Relative risks of medication use were calculated.Results: A total of 14,491 individuals with multiple sclerosis and 144,910 matched controls were included. Patients with multiple sclerosis had significantly higher use of several therapeutic drug classes, including analgesics (51% vs. 33%; RR: 1.56, 95% CI: 1.52-1.60), agents for constipation (12% vs. 3%; RR: 4.61, 95% CI: 4.36-4.88), spasmolytics, and urological medications. Among specific drugs, the most pronounced differences were observed for modafinil (RR: 323.33, 95% CI: 228.67-457.19), baclofen (RR: 36.51, 95% CI: 33.33-39.99), and fesoterodine (RR: 36.36, 95% CI: 18.66-70.87). In contrast, individuals with multiple sclerosis had lower usage of antidiabetic medications and treatments for chronic obstructive pulmonary disease.Interpretation: This large, population-based study reveals extensive use of medications targeting symptoms and comorbidities in individuals with multiple sclerosis. These insights can guide healthcare providers in optimizing patient management, addressing overlooked treatment needs, and improving overall care.","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acn3.70155","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease-modifying therapies.

Methods: We conducted a nationwide, registry-based study in Denmark. All residents with a diagnosis of multiple sclerosis aged 20-80 years and alive on January 1, 2023, were included and followed for 1 year. Each patient was matched with 10 individuals from the general population based on age, sex, and residence. Prescription data were obtained from the Danish National Prescription Registry and categorized using the Anatomical Therapeutic Chemical classification. Relative risks of medication use were calculated.

Results: A total of 14,491 individuals with multiple sclerosis and 144,910 matched controls were included. Patients with multiple sclerosis had significantly higher use of several therapeutic drug classes, including analgesics (51% vs. 33%; RR: 1.56, 95% CI: 1.52-1.60), agents for constipation (12% vs. 3%; RR: 4.61, 95% CI: 4.36-4.88), spasmolytics, and urological medications. Among specific drugs, the most pronounced differences were observed for modafinil (RR: 323.33, 95% CI: 228.67-457.19), baclofen (RR: 36.51, 95% CI: 33.33-39.99), and fesoterodine (RR: 36.36, 95% CI: 18.66-70.87). In contrast, individuals with multiple sclerosis had lower usage of antidiabetic medications and treatments for chronic obstructive pulmonary disease.

Interpretation: This large, population-based study reveals extensive use of medications targeting symptoms and comorbidities in individuals with multiple sclerosis. These insights can guide healthcare providers in optimizing patient management, addressing overlooked treatment needs, and improving overall care.

查看原文本刊更多论文

多发性硬化症的药物使用：与丹麦普通人群的基于人群的比较

目的：调查与普通人群相比，多发性硬化症患者处方药的总体使用情况，重点关注除疾病改善疗法之外的治疗方法。方法：我们在丹麦进行了一项全国性的、基于登记的研究。所有在2023年1月1日存活的20-80岁的多发性硬化症患者被纳入研究，随访1年。每名患者根据年龄、性别和居住地与10名普通人群相匹配。处方数据从丹麦国家处方登记处获得，并使用解剖治疗化学分类进行分类。计算药物使用的相对风险。结果：共有14491名多发性硬化症患者和144910名匹配的对照组被纳入研究。多发性硬化症患者对几种治疗药物的使用明显更高，包括镇痛药(51% vs 33%；RR: 1.56, 95% CI: 1.52-1.60)，便秘药物(12% vs. 3%；RR: 4.61, 95% CI: 4.36-4.88)、解痉药和泌尿科药物。在特异性药物中，莫达非尼（RR: 323.33, 95% CI: 228.67 ~ 457.19）、巴氯芬（RR: 36.51, 95% CI: 33.33 ~ 39.99）和非索罗定（RR: 36.36, 95% CI: 18.66 ~ 70.87）的差异最为显著。相比之下，患有多发性硬化症的人使用抗糖尿病药物和治疗慢性阻塞性肺病的药物较少。这项基于人群的大型研究揭示了针对多发性硬化症患者症状和合并症的药物的广泛使用。这些见解可以指导医疗保健提供者优化患者管理，解决被忽视的治疗需求，并改善整体护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)

CiteScore

9.10

自引率

1.90%

发文量

218

审稿时长

8 weeks

期刊介绍： Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.